The goal of this implementation trial is to evaluate at least two alternative delivery strategies and adherence support for malaria chemoprevention with dihydroartemisinin-piperaquine in the post-discharge management of children hospitalised with severe anaemia or severe malaria to optimise adherence in Kenya. The actual interventions to be evaluated have been co-designed with national stakeholders during an initial formative research stage.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of eligible children who received 3 courses of PDMC
Timeframe: 2, 6 and 10 weeks post discharge
Proportion of study children who adhered to 3 PDMC courses (9 doses)
Timeframe: 2, 6 and 10 weeks (days 1-3) post discharge